Soligenix Inc SNGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNGX is a good fit for your portfolio.
News
-
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
-
Soligenix Announces Pricing of $4.75 Million Public Offering
-
Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA
-
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
-
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
-
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
-
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
-
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
Trading Information
- Previous Close Price
- $0.42
- Day Range
- $0.42–0.43
- 52-Week Range
- $0.37–4.20
- Bid/Ask
- $0.42 / $0.43
- Market Cap
- $5.98 Mil
- Volume/Avg
- 60,787 / 2.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 15
- Website
- https://www.soligenix.com
Valuation
|
Metric
|
SNGX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.71 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SNGX
|
|---|---|
Quick Ratio | 1.40 |
Current Ratio | 1.55 |
Interest Coverage | −159.97 |
Quick Ratio
SNGX
Profitability
|
Metric
|
SNGX
|
|---|---|
Return on Assets (Normalized) | −47.33% |
Return on Equity (Normalized) | −426.90% |
Return on Invested Capital (Normalized) | −78.85% |
Return on Assets
SNGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vbzydvqch | Wfd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Spjdjlxyr | Htlskhz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bgvdyzmzc | Thrvdjb | $97.8 Bil | |
MRNA
| Moderna Inc | Tdvjrfz | Fmwg | $41.3 Bil | |
ARGX
| argenx SE ADR | Kxkgyxfmk | Wyh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Chwcjsz | Nks | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dzjlmlfp | Lhmkzbh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hbvsjfdfg | Rtrhql | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nmvsvddlx | Fdsjpq | $12.5 Bil | |
INCY
| Incyte Corp | Khhtppqzc | Bwqyy | $11.6 Bil |